Gland Pharma Limited is a leading global player in the generic injectables market, with a robust manufacturing and R&D capability. The company operates on a B2B model, serving over 60 countries including the U.S., Europe, and India.

The company reported a 6% YoY growth in Q2 FY26 revenue driven by strong U.S. market performance, new product launches, and expansion in the CDMO sector.

Gland Pharma is strategically expanding its capacity, focusing on high-growth sectors such as GLP-1 manufacturing and complex injectables, aligning with the global trends in specialty pharma and biologics.

Recent strategic acquisitions, including Cenexi, enhance Gland Pharma's capabilities in biotechnology and biologics, supporting its transformation into an innovation-driven CDMO and specialty injectables leader.

The company's focus on R&D is evident with significant investment aimed at developing complex injectables and innovative delivery systems, strengthening its competitive edge in the high-value pharmaceuticals market.